Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Ruben G.W. Quek"'
Autor:
Josephine Louella Feliciano, Dylan McLoone, Yingxin Xu, Ruben G.W. Quek, Andreas Kuznik, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel, Patricia Guyot, Gerasimos Konidaris, Keith Chan, Sam Keeping, Florence R. Wilson, Nick Freemantle
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
ObjectivesIn randomized-controlled crossover design trials, overall survival (OS) treatment effect estimates are often confounded by the control group benefiting from treatment received post-progression. We estimated the adjusted OS treatment effect
Externí odkaz:
https://doaj.org/article/c18f66be84a1487fa49aaa999318f8aa
Autor:
Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Ana Baramidze, Davit Giorgadze, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Siyu Li, Yuntong Li, Manika Kaul, Ruben G.W. Quek, Jean-Francois Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel
Publikováno v:
Journal of Thoracic Oncology. 18:755-768
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::471d98be988cf1e0f39efc2cd914cbc2
https://doi.org/10.1016/j.jtho.2023.03.008
https://doi.org/10.1016/j.jtho.2023.03.008
Autor:
Karl D. Lewis, Timothy J. Inocencio, Ruben G.W. Quek, Patrick R. LaFontaine, Zeynep Eroglu, Anne Lynn S. Chang, Cristina Ivanescu, Alexander J. Stratigos, Ketty Peris, Aleksandar Sekulic, Matthew G. Fury, Chieh-I Chen
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:HSR23-097
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20ed5428d8a0888fc8dedc051b3195da
https://doi.org/10.6004/jnccn.2022.7161
https://doi.org/10.6004/jnccn.2022.7161
Autor:
Catherine Thieblemont, Qiufei Ma, Christian Hampp, James Harnett, Rachel E. Sobel, Jessica J. Jalbert, Ruben G.W. Quek, Wenhui Wei, Ning Wu, Vera Mastey, Joy Wang, Anit Bajwa, Benedikt Maissenhaelter, Chantal van Gils, Shivani Aggarwal, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Emmanuel Bachy, Gandhi Laurent Damaj
Publikováno v:
Blood. 140:8065-8067
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d501f279f8273c00da501e6bd7e2d24
https://doi.org/10.1182/blood-2022-158418
https://doi.org/10.1182/blood-2022-158418
Autor:
Emmanuel Bachy, Gandhi Laurent Damaj, Qiufei Ma, Christian Hampp, James Harnett, Rachel E. Sobel, Jessica J. Jalbert, Ruben G.W. Quek, Wenhui Wei, Ning Wu, Vera Mastey, Joy Wang, Anit Bajwa, Benedikt Maissenhaelter, Chantal van Gils, Shivani Aggarwal, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Catherine Thieblemont
Publikováno v:
Blood. 140:5198-5200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f319a24b0ac442777561cf86250fda9
https://doi.org/10.1182/blood-2022-158419
https://doi.org/10.1182/blood-2022-158419
Publikováno v:
Leukemia & Lymphoma. 63:54-63
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) treatments have been rapidly evolving for patients treated in later lines of therapy (LoT). Country-specific cancer registry data for the US and Western Europe (WE) were combined with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::035ef62c6874fc5942a64c36721e1563
https://doi.org/10.1080/10428194.2021.1975188
https://doi.org/10.1080/10428194.2021.1975188
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:EPR21-034
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4992eb8ef7fa650b49160f57fb7cea7
https://doi.org/10.6004/jnccn.2020.7742
https://doi.org/10.6004/jnccn.2020.7742
Autor:
A. Niyazov, Michael P. Lux, Ruben G.W. Quek, Thomas Decker, Norbert Marschner, Nadia Harbeck, Eva Diana Runkel
Publikováno v:
Breast Care. 17:40-46
Introduction: Diagnostic testing of germline mutations in breast cancer susceptibility genes 1 or 2 (gBRCA1/2) in patients with human epidermal growth factor receptor 2 negative (HER2–) advanced breast cancer (ABC; locally advanced or metastatic br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3dd4848364e60bbd21d5048236de9403
https://doi.org/10.1159/000513596
https://doi.org/10.1159/000513596
Autor:
Johannes Ettl, Rinat Yerushalmi, Joanne L. Blum, Henri Roché, Sami Diab, A. Goncalves, Natasha Woodward, Sara A. Hurvitz, Lida A. Mina, Yunjoo Im, Tiziana Usari, Wolfgang Eiermann, Miguel Martin, Ruben G.W. Quek, Hope S. Rugo, Kiheon Lee, Akos Czibere, Silvana Lanzalone, Jennifer K. Litton, Annabel Goodwin
Publikováno v:
Annals of Oncology. 31:1526-1535
Background In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P Patients and methods This randomized phase III trial enrolled patients with gBRCA1/2-mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e3e264b346dff405e101a6d968856fe
https://doi.org/10.1016/j.annonc.2020.08.2098
https://doi.org/10.1016/j.annonc.2020.08.2098
Autor:
Anthony Gonçalves, Johannes Ettl, Ruben G.W. Quek, Hope S. Rugo, H. Bhattacharyya, Sara A. Hurvitz
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:CLO20-039
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d69a68f6eb2a48e9d25d361f358b9a57
https://doi.org/10.6004/jnccn.2019.7390
https://doi.org/10.6004/jnccn.2019.7390